![]() Spinogenix Spinogenix is a company that develops therapeutics restoring the brain connections and functions lost in brain injury and neurodegenerative diseases. | ![]() Regenevita Regenevita BioCell is a company that provides regenerative medicine products and therapy commercialization services. | ![]() JCR Pharmaceuticals JCR Pharmaceuticals is a company that specializes in the development of pharmaceutical products. | ![]() Travere Therapeutics Travere Therapeutics is a biopharmaceutical company that focuses on the development, acquisition, and commercialization of therapies for the treatment of serious or rare diseases. | |
Founding Date | Founding Date 2016 | Founding Date N/A | Founding Date 1975 | Founding Date 2011 |
Type | Type Private | Type Private | Type Public | Type Public |
Tags | ||||
Locations | Locations HQ | Locations Houston, US HQ | Locations Ashiya, JP HQ Kobe, JP Kobe, JP Kobe, JP Kobe, JP | Locations San Diego, US HQ Dublin, IE |
Employees | Employees 4 | Employees 3 | Employees 934 | Employees 46293% increase |
Valuation ($) | Valuation ($) N/A | Valuation ($) N/A | Valuation ($) 533.9 m | Valuation ($) 1.4 b |
Financial | ||||
Revenue (est.) | Revenue (est.) N/A | Revenue (est.) N/A | Revenue (est.) ¥40.3b (FY, 2026) | Revenue (est.) $490.7m (FY, 2025) |
Cost of goods | Cost of goods N/A | Cost of goods N/A | Cost of goods ¥7.6b (FY, 2026) | Cost of goods $10.3m (FY, 2025) |
Gross profit | Gross profit N/A | Gross profit N/A | Gross profit ¥32.7b (FY, 2026) | Gross profit $480.4m (FY, 2025) |
Net income | Net income N/A | Net income N/A | Net income ¥2.2b (FY, 2026) | Net income ($25.5m) (FY, 2025) |

Regenevita BioCell is a company that provides regenerative medicine products and therapy commercialization services.
View company
JCR Pharmaceuticals is a company that specializes in the development of pharmaceutical products.
View company
Travere Therapeutics is a biopharmaceutical company that focuses on the development, acquisition, and commercialization of therapies for the treatment of serious or rare diseases.
View company